This can be achieved by employing light with a carefully designed spectral composition that primarily activates rods and cones while avoiding melanopsin activation or using melanopsin inhibitors, thereby slowing the progression of myopia and/or reducing its severity 185. The gene discussed is OPN4; the disease is myopia.